The financing values the biotechnology company at $800m and will support its in vivo cell therapy pipeline.
"We believe the future of medicine lies in reprogramming the body to repair itsel. We design the models and the medicines to teach it howf"
Portfolio
4
companies
Basecamp Research
A biotechnology company developing biological foundation models and cell therapies.

Immersive Labs
Immersive Labs provides a cybersecurity platform to measure and improve human cyber skills across organisations.
Insurdata
Insurdata supplies granular risk data and exposure analytics to the insurance industry.
Meticulous
Meticulous automates software testing to verify code changes before deployment.
Venky Ganesan
Partner
The financing values the biotechnology company at $800m and will support its in vivo cell therapy pipeline.
"We believe the future of medicine lies in reprogramming the body to repair itsel. We design the models and the medicines to teach it howf"
Chemistry led the Series A round to support research, development, and team expansion.

Insight Partners led the Series C financing, which included participation from Menlo Ventures, Citi Ventures and Goldman Sachs Asset Management.
"With cyber risk becoming a problem for a growing number of business functions, cybersecurity knowledge and skills should no longer be the preserve of a few technical people hidden away in a back office. Everyone from the teams who build software, to the CEO, now need to play their part in addressing a pervasive company issue. This requires unlocking and evidencing skills in a much broader group of people."
Anthemis and Menlo Ventures led the financing round alongside five new venture capital firms and angel investors.
"We are delighted to have secured the backing of a fantastic range of investors who fully understand the criticality of the service that Insurdata provides to the re/insurance market. Our work to date has exposed material deficiencies in the quality and scope of information which underwriters are reliant upon, which in turn have a detrimental effect on their ability to accurately price risk and manage portfolios effectively."